Bristol Myers Squibb Triggers $15 Million Milestone in RNA Cardiovascular Collaboration
Bristol Myers Squibb paid a $15 million milestone to Atrium Therapeutics after delivery of the first RNA-based cardiology development candidate under their collaboration. Under the deal, Atrium can earn up to $1.35 billion in R&D milestones, $825 million in commercial milestones and tiered low-double-digit royalties while BMS funds all development.
1. Milestone Payment Awarded
Bristol Myers Squibb has disbursed $15 million to Atrium Therapeutics as the first development milestone under their global cardiovascular RNA collaboration, following delivery of the initial cardiology-targeted RNA candidate.
2. Collaboration Agreement Terms
Under the global licensing and research pact, Atrium stands to receive up to $1.35 billion in R&D milestones and $825 million in commercial milestones, plus tiered low-double-digit royalties on net sales, while Bristol Myers Squibb covers all future clinical development, regulatory filings and commercialization expenses.
3. Pipeline Implications
The delivered candidate represents the first licensed RNA-based therapy for cardiomyopathies in this collaboration, enhancing Bristol Myers Squibb’s cardiovascular pipeline and underscoring the potential of targeted RNA delivery technology to address genetic drivers of cardiac disease.